SGMT

MKT CAP:$187M

Sagimet Biosciences Inc.

Market Cap

$187M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$5.87-$0.12 (-2.00%)

Apr 23, 2026

Company Details

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug c...

CEO

David A. Happel

IPO Date

Jul 17, 2023

Website

sagimet.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$51M

EPS (Diluted)

-$1.58

Free Cash Flow

-$46M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q1 2026

May 14, 2026

PENDING

FY 2025

Mar 11, 2026

$0EPS -$1.58

Q4 2025

Mar 11, 2026

$0EPS -$0.30

Q3 2025

Nov 13, 2025

$0EPS -$0.40

Q2 2025

Aug 13, 2025

$0EPS -$0.32

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$0	$0	-$9M
Q2 22	$0	$0	-$7M
Q3 22	$0	$0	-$8M
Q4 22	$0	$0	-$7M
Q1 23	$0	$0	-$7M
Q2 23	$0	$0	-$7M
Q3 23	$2M	$2M	-$7M
Q4 23	$0	$0	-$9M
Q1 24	$0	$0	-$9M
Q2 24	$0	$0	-$11M
Q3 24	$0	$0	-$17M
Q4 24	$0	$0	-$18M
Q1 25	$0	$0	-$20M
Q2 25	$0	$0	-$12M
Q3 25	$0	$0	-$14M
Q4 25	$0	$0	-$11M

Valuation

Quarter	P/S	P/E
Q1 22	—	—
Q2 22	—	—
Q3 22	—	—
Q4 22	—	—
Q1 23	—	—
Q2 23	—	—
Q3 23	69.3x	—
Q4 23	74.3x	—
Q1 24	83.5x	—
Q2 24	50.4x	—
Q3 24	—	—
Q4 24	—	—
Q1 25	—	—
Q2 25	—	—
Q3 25	—	—
Q4 25	—	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$5M	-$5M
Q2 22	-$6M	-$6M
Q3 22	-$6M	-$6M
Q4 22	-$7M	-$7M
Q1 23	-$7M	-$7M
Q2 23	-$6M	-$6M
Q3 23	-$4M	-$4M
Q4 23	-$7M	-$7M
Q1 24	-$6M	-$6M
Q2 24	-$6M	-$6M
Q3 24	-$20M	-$20M
Q4 24	-$11M	-$11M
Q1 25	-$15M	-$15M
Q2 25	-$9M	-$9M
Q3 25	-$10M	-$10M
Q4 25	-$12M	-$12M

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	—	-22.6%
Q2 23	—	-2.5%
Q3 23	—	+23.0%
Q4 23	—	+28.1%
Q1 24	—	+29.6%
Q2 24	—	+50.0%
Q3 24	-100.0%	+78.8%
Q4 24	—	+92.2%
Q1 25	—	+126.6%
Q2 25	—	+12.6%
Q3 25	—	-15.2%
Q4 25	—	-40.8%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$0	—
Q2 22	$383.0K	—
Q3 22	$389.0K	—
Q4 22	$721.0K	—
Q1 23	$767.0K	—
Q2 23	$1M	—
Q3 23	$2M	92.8%
Q4 23	$1M	—
Q1 24	$759.0K	—
Q2 24	$1M	—
Q3 24	$2M	—
Q4 24	$2M	—
Q1 25	$1M	—
Q2 25	$2M	—
Q3 25	$2M	—
Q4 25	$2M	—

OpEx Breakdown

Quarter	R&D	G&A
Q1 22	$6M	$3M
Q2 22	$6M	$867.0K
Q3 22	$7M	$848.0K
Q4 22	$6M	$2M
Q1 23	$4M	$2M
Q2 23	$5M	$2M
Q3 23	$5M	$4M
Q4 23	$6M	$4M
Q1 24	$5M	$4M
Q2 24	$6M	$4M
Q3 24	$13M	$4M
Q4 24	$14M	$4M
Q1 25	$15M	$5M
Q2 25	$7M	$5M
Q3 25	$10M	$5M
Q4 25	$7M	$4M

War Chest

Quarter	Cash	Short-term Investments	Total
Q4 22	$158.0K	$32M	$32M
Q1 23	$12M	$13M	$25M
Q2 23	$19M	$0	$19M
Q3 23	$102M	$0	$102M
Q4 23	$75M	$20M	$95M
Q1 24	$177M	$17M	$194M
Q2 24	$96M	$70M	$166M
Q3 24	$77M	$75M	$152M
Q4 24	$76M	$75M	$151M
Q1 25	$65M	$80M	$145M
Q2 25	$42M	$83M	$125M
Q3 25	$32M	$84M	$117M
Q4 25	$35M	$78M	$113M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	22M	—	—
Q2 22	22M	0.0%	—
Q3 22	22M	0.0%	—
Q4 22	22M	0.0%	—
Q1 23	22M	0.0%	0.0%
Q2 23	22M	0.0%	0.0%
Q3 23	18M	-17.9%	-17.9%
Q4 23	18M	0.0%	-17.9%
Q1 24	29M	+59.6%	+31.0%
Q2 24	32M	+9.9%	+43.9%
Q3 24	32M	+0.7%	+76.7%
Q4 24	32M	+0.2%	+76.9%
Q1 25	32M	0.0%	+10.9%
Q2 25	32M	+0.0%	+0.9%
Q3 25	32M	+0.8%	+1.0%
Q4 25	32M	-0.4%	+0.5%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	—	—
Q2 22	—	—
Q3 22	—	—
Q4 22	—	—
Q1 23	—	—
Q2 23	—	—
Q3 23	—	—
Q4 23	$0	10
Q1 24	$0	10
Q2 24	$0	10
Q3 24	$0	10
Q4 24	$0	14
Q1 25	$0	14
Q2 25	$0	14
Q3 25	$0	14
Q4 25	$0	1K

Revenue / Employee